{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-016179","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.961270+00:00","generated_at":"2026-05-15T06:45:02.534373+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AIM ImmunoTech amends ATM agreement to remove $3M cap on share sales","bullets":["Amendment No. 1 to Equity Distribution Agreement with Maxim Group removes the prior $3,000,000 limit on shares sold.","Company's common stock continues to be offered at-the-market under existing shelf registration statement (Form S-3).","A prospectus supplement was filed to increase the number of shares available for sale in the offering.","Maxim Group remains the exclusive sales agent for the at-the-market offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-016179","json":"https://secwatch.observer/filing/0001493152-26-016179.json","markdown":"https://secwatch.observer/filing/0001493152-26-016179.md","text":"https://secwatch.observer/filing/0001493152-26-016179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:45:02.534373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c37b58aab0cffdfe9c1ba27f7a684443f5f34ab7","claim":"AIM ImmunoTech Inc. amended Amendment No. 1 with Maxim Group LLC (effective 2026-04-10).","evidence_excerpt":"On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-064037","ticker":"OSRH","company_name":"OSR Holdings, Inc.","filed_at":"2026-06-02T17:16:53+00:00","headline":"OSR Holdings enters $30M asset purchase agreement with subsidiary Vaximm for VXM01 IP","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-064037","json":"https://secwatch.observer/filing/0001213900-26-064037.json","markdown":"https://secwatch.observer/filing/0001213900-26-064037.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026064037/0001213900-26-064037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026064037/ea0293037-8k_osrhold.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","comparable_excerpt":"On May 27, 2026, OSR Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vaximm AG (“Vaximm”), a clinical-stage biopharmaceutical company organized under the laws of Switzerland.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026064037/0001213900-26-064037-index.htm"}},{"accession":"0001213900-26-063834","ticker":"VTIX","company_name":"Virtuix Holdings Inc.","filed_at":"2026-06-02T13:15:39+00:00","headline":"Virtuix amends warrants to $4.00 exercise price, extends period to July 27, 2026","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063834","json":"https://secwatch.observer/filing/0001213900-26-063834.json","markdown":"https://secwatch.observer/filing/0001213900-26-063834.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606242/000121390026063834/0001213900-26-063834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606242/000121390026063834/ea0292972-8k_virtuix.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","comparable_excerpt":"On June 1, 2026, Virtuix Holdings Inc. (the “Company”) entered into amendments to each of the following warrants to purchase shares of Class A Common Stock (collectively, the “Warrant Amendments”) with Streeterville Capital, LLC (the “Investor”) amending the exercise price and extending the Reduced Exercise Price Period (as defined below) to each such warrant","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1606242/000121390026063834/0001213900-26-063834-index.htm"}},{"accession":"0001193125-26-252560","ticker":"CURB","company_name":"Curbline Properties Corp.","filed_at":"2026-06-02T12:07:02+00:00","headline":"Curbline Properties enters up to $400M ATM equity offering; prior program terminated","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252560","json":"https://secwatch.observer/filing/0001193125-26-252560.json","markdown":"https://secwatch.observer/filing/0001193125-26-252560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2027317/000119312526252560/0001193125-26-252560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2027317/000119312526252560/d111894d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","comparable_excerpt":"On June 2, 2026, Curbline Properties Corp. (the “ Company ”) and Curbline Properties LP (the “ Operating Partnership ”) entered into an ATM Equity Offering Sales Agreement (the “ Equity Sales Agreement ”) with Jefferies LLC, BNY Mellon Capital Markets, LLC, BofA Securities, Inc., BTIG, LLC, Capital One Securities, Inc., Goldman Sachs & Co. LLC, KeyBanc Capital Markets Inc., Morgan Stanley & Co. LLC, Nomura Securities International, Inc., StoneX Financial Inc. and Wells Fargo Securities, LLC, as sales agents","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2027317/000119312526252560/0001193125-26-252560-index.htm"}},{"accession":"0001213900-26-063767","ticker":"BJDX","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2026-06-02T10:30:41+00:00","headline":"Bluejay Diagnostics partners with Argonaut for US-based Symphony platform manufacturing","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063767","json":"https://secwatch.observer/filing/0001213900-26-063767.json","markdown":"https://secwatch.observer/filing/0001213900-26-063767.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/0001213900-26-063767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/ea0293118-8k_bluejay.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","comparable_excerpt":"On May 27, 2026, Bluejay Diagnostics, Inc. (the “Company”) entered into an agreement and statement of work (together, the “Agreement”) with Argonaut Manufacturing Services c/o Argonaut, Inc. (“Argonaut”) regarding the provision by Argonaut to the Company of certain manufacturing services to support the Company’s SymphonyTM platform.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/0001213900-26-063767-index.htm"}},{"accession":"0001193125-26-252407","ticker":"FLY","company_name":"Firefly Aerospace Inc.","filed_at":"2026-06-02T10:21:08+00:00","headline":"Firefly Aerospace prices secondary offering of 12M shares at $48.00 per share","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252407","json":"https://secwatch.observer/filing/0001193125-26-252407.json","markdown":"https://secwatch.observer/filing/0001193125-26-252407.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860160/000119312526252407/0001193125-26-252407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860160/000119312526252407/d156539d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","comparable_excerpt":"On May 28, 2026, in connection with the pricing of the Offering, the Company entered into an underwriting agreement (the \"Underwriting Agreement\") with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters listed on Schedule I thereto","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1860160/000119312526252407/0001193125-26-252407-index.htm"}},{"accession":"0001140361-26-023619","ticker":"GNK","company_name":"GENCO SHIPPING & TRADING LTD","filed_at":"2026-06-02T10:01:31+00:00","headline":"Genco Shipping amends shareholder rights plan, eliminates 'Acting in Concert' definition","event_type":"other_material","sec_items":["1.01","3.03","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023619","json":"https://secwatch.observer/filing/0001140361-26-023619.json","markdown":"https://secwatch.observer/filing/0001140361-26-023619.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326200/000114036126023619/0001140361-26-023619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326200/000114036126023619/ef20075333_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","comparable_excerpt":"On June 2, 2026, Genco Shipping & Trading Limited (the “ Company ”) entered into the Third Amendment to Shareholders Rights Agreement (the “ Third Amendment ”) to amend the Shareholder Rights Agreement, dated as of October 1, 2025 between the Company and Computershare Inc., as amended to date (the “ Rights Agreement ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326200/000114036126023619/0001140361-26-023619-index.htm"}},{"accession":"0001193125-26-251994","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-06-01T23:13:20+00:00","headline":"Tempest Therapeutics enters warrant exercise inducement for ~$2M; issues new warrants to purchase 2.34M shares at $1.73","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251994","json":"https://secwatch.observer/filing/0001193125-26-251994.json","markdown":"https://secwatch.observer/filing/0001193125-26-251994.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/d105562d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","comparable_excerpt":"On May 28, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a warrant exercise and inducement offer letter agreement (the “ Inducement Letter ”) with a holder of certain existing warrants to purchase shares of the Company’s common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm"}},{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}